http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022123236-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67bf280a23817fdc0f1cd4dc93ff0b98
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
filingDate 2021-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_054e2894f5147190319d1a1076edb634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42b5431384f62a7916e5d7a967802922
publicationDate 2022-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022123236-A1
titleOfInvention Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes in patients taking brivaracetam
abstract The present invention relates to the use of cannabidiol (CBD) and an anti-epileptic drug (AED), brivaracetam (BRV), for the treatment of seizures associated with epilepsy syndromes. In particular the types of seizures treated include atonic, tonic, tonic-clonic, and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
priorityDate 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019207319-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019180706-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020225540-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016160542-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226491388
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3331
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2789
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID66672
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16078
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3016
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226582593
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID129228
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421683
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID66672
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226493435
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226424351
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226593560
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644019
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421598
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2802
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226490700
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45783233
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396574
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6792
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3878
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226443145
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410725
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID219078
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9837243
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441341

Total number of triples: 52.